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Abstract
Hereditary Hemochromatosis (HH) is a recessively inherited disorder of iron overload occurring commonly in subjects
homozygous for the C282Y mutation in HFE gene localized on chromosome 6p21.3 in linkage disequilibrium with the
human leukocyte antigen (HLA)-A locus. Although its genetic homogeneity, the phenotypic expression is variable
suggesting the presence of modifying factors. One such genetic factor, a SNP microhaplotype named A-A-T, was recently
found to be associated with a more severe phenotype and also with low CD8+T-lymphocyte numbers. The present study
aimed to test whether the predictive value of the A-A-T microhaplotype remained in other population settings. In this study
of 304 HH patients from 3 geographically distant populations (Porto, Portugal 65; Alabama, USA 57; Nord-Trøndelag,
Norway 182), the extended haplotypes involving A-A-T were studied in 608 chromosomes and the CD8+ T-lymphocyte
numbers were determined in all subjects. Patients from Porto had a more severe phenotype than those from other settings.
Patients with A-A-T seemed on average to have greater iron stores (p = 0.021), but significant differences were not
confirmed in the 3 separate populations. Low CD8+ T-lymphocytes were associated with HLA-A*03-A-A-T in Porto and
Alabama patients but not in the greater series from Nord-Trøndelag. Although A-A-T may signal a more severe iron
phenotype, this study was unable to prove such an association in all population settings, precluding its use as a universal
predictive marker of iron overload in HH. Interestingly, the association between A-A-T and CD8+ T-lymphocytes, which was
confirmed in Porto and Alabama patients, was not observed in Nord-Trøndelag patients, showing that common HLA
haplotypes like A*01–B*08 or A*03–B*07 segregating with HFE/C282Y in the three populations may carry different
messages. These findings further strengthen the relevance of HH as a good disease model to search for novel candidate loci
associated with the genetic transmission of CD8+ T-lymphocyte numbers.
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Introduction
The major histocompatibility complex (MHC) region on
chromosome 6p21.3 constitutes the most dense gene region of
the human genome. It has been estimated that 40% of classical
MHC genes are expressed in the immune system [1]. These genes
are physically clustered, possibly reflecting functional relationships,
and are characterized by high polymorphism levels and strong
linkage disequilibrium. These characteristics make the MHC
region a paradigm in many aspects of genomic research,
particularly in disease association studies. Genetic variation in
the MHC is associated with more disorders than any other
genomic region, the majority of which are immune-related.
Nevertheless, fine mapping of those disease associations and the
identification of specific functional variants remain difficult. Both
structural and regulatory variants are important in disease
associations and may operate in tandem [1].
A classic example of disease association with extreme linkage
disequilibrium at the MHC region is Hereditary Hemochroma-
tosis (HH), an autosomal recessive disorder of primary iron
overload characteristically found in Caucasians and associated
with homozygosity for the HFE p.Cys282Tyr mutation (C282Y) in
the vast majority of cases. HFE encodes a non-classical MHC
class-I molecule and is localized 4 Mb telomeric to HLA-A [2], in
very strong association with an ancestral haplotype carrying the
human leukocyte antigen (HLA) antigens A*03 and B*07 [3,4]. By
applying several types of linkage-disequilibrium calculations to
analyze the HH locus, Ajioka and co-workers found very high
disequilibrium values over a large region from 150 kb centromeric
to 5 Mb telomeric of HLA-A, partly due to an unusual low
recombination rate of approximately 28% of the expected value
[5]. In the same study, a haplotype phylogeny for HH
chromosomes suggested that the origin of HFE C282Y is recent.
These observations also provided a plausible explanation for
previous difficulties in localizing the HH gene [6,7].
Despite the genetic homogeneity at HFE among HH patients,
their iron phenotypes are highly variable. Consequently, possible
environmental and genetic modifiers of iron phenotypes in
hemochromatosis have been intensively investigated. Among
others, genes within the MHC class I region, inherited in linkage
with the ancestral C282Y-containing haplotype, have been
implicated in the clinical heterogeneity of HFE-associated HH
[8]. However, conflicting results obtained by different authors
have still not solved this question. Earlier independent studies in
geographically different populations have shown that the number
of copies of the common ancestral haplotype HLA-A*03–B*07
was associated with the expression of iron phenotypes. Patients
with two copies of the ancestral haplotype were shown to have
more severe iron overload phenotypes than those with one or no
copy of the ancestral haplotype in studies performed in Australia,
Italy and Alabama, USA [9–12]. Moreover, Pratiwi et al. showed
by extended linkage disequilibrium analysis in patients from
Australia that there are two distinct peaks of association separated
by 2 Mb in the region of HFE, a pattern not expected for a single
gene disorder [13]. This suggested that a gene modifying the
phenotype of C282Y homozygotes could be localized around the
area of D6S105. More recent studies did not support the previous
observations [14–17]. In a review of the origin and spread of the
hemochromatosis mutation, Distante and co-workers [14] report-
ed that although associations of HLA haplotypes with the severity
of iron overload were described, no such relationship was found in
patients from the UK (R. Raha-Chowdhury, A. Bomford and M.
Worwood, unpublished data). In another study of 8 HH families
from Britanny, France, Sachot and co-workers analyzed C282Y
homozygous relatives with no clinical signs of the iron overload in
comparison to the respective probands who had abnormal iron
phenotypes. They found no evidence that either HFE polymor-
phisms or variants in 10 microsatellite markers surrounding HFE
could explain phenotypic variability in the respective kinships [15].
Barton and co-workers extended their study of genotype/
phenotype correlations to a population of 141 C282Y homozygous
probands from Alabama, USA, and did not reproduce the
previous observations that were based on a relatively small
number of probands [16]. Finally, in a study of HLA haplotypes of
HH patients in a rural population from a former Norwegian
province in Central Sweden, Olsson and co-workers could not find
an association of the HLA-A*03 with the iron phenotype.
Interestingly however, they found that males with double copies
of the very common A*01–B*08 haplotype expressed a milder
phenotype, supporting again an association of iron overload with
the MHC region, but in the setting of a different haplotype [17].
Altogether the above described studies demonstrate that
associations between the HH phenotype and the classical HLA
markers vary among different cohorts from geographically distinct
populations (who naturally diverge due to genetic drift or
recombination events) and point to the necessity to look for novel
markers at the MHC region that may help explaining the
phenotypic variability in HH patients. One such factor could be a
new 500 kb microhaplotype localized between HFE and the HLA-
A locus as described by Cruz and coworkers [18]. This haplotype
was associated with a more severe phenotype in its carriers and
also with low CD8+ T lymphocyte numbers, which in previous
studies from Portugal have predicted a more severe iron overload
[19–22]. Low lymphocyte numbers were also associated with a
more severe phenotype in patients from Alabama in particular
those with HLA-A*01–B*08 [23]. However, this same haplotype
reported in a former Norwegian province seemed to be associated
with a milder phenotype [17]. Unfortunately, no data are available
regarding CD8+T lymphocyte numbers in this population from
Central Sweden.
In the present study we sought to test whether the predicting
value of the microhaplotype described by Cruz et al. [18] could be
reproduced in other settings, i.e., in different populations from
geographically distant regions. In this context, we explored the
degree of conservation of the reported HH-associated haplotypes
in relation to their effect on the low CD8+ T lymphocyte
phenotype or the clinical expression of iron overload. Our data
indicate that although the same haplotypes are observed in distant
geographical regions, their relative frequencies are variable, which
may explain differences in genotype/phenotype associations
among different populations.
Methods
Ethics Statement
The study was approved by the Ethical Committees of Centro
Hospitalar do Porto, Porto; Institutional Review Board of
Brookwood Medical Center, Alabama and The Regional Com-
mittee for Medical and Health Research Ethics, REC Central,
Trondheim. Written informed consent was obtained from
participants according to the Helsinki declaration.
Study Populations & Clinical Data
Three different populations of Hereditary Hemochromatosis
patients from geographically distant regions were included in this
study. The only inclusion criteria for the purpose of the study were
the confirmation of homozygosity for the C282Y HFE mutation
and to be an adult, because the CD8+ T lymphocyte phenotype is
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stable in adults. The first group included 65 unselected, unrelated
HH patients from the north of Portugal, mainly from the Porto
district area, consecutively identified between 1985 and 2011 in
non-screening settings and regularly followed up at the Hemo-
chromatosis Outpatient Clinic of Santo Anto´nio Hospital, Porto
and Predictive and Preventive Genetic Centre, Porto. This group
of patients is designated as Porto patients. The second group of
patients included 57 unrelated HH patients diagnosed in non-
screening settings from central Alabama, USA, diagnosed between
1988 and 2010 and treated at Southern Iron Disorders Center,
Birmingham, Alabama. These probands were selected for the
present study only because they presented for diagnosis or
treatment in a consecutive mode. This group of patients is
designated as Alabama patients. The third group of patients
included 182 patients from the Nord-Trøndelag County, Norway,
who were diagnosed with HH as part of a population screening
study (HUNT2) between 1995 and 1997, and were followed up at
St. Olav Hospital, Trondheim. This group of patients is designated
as Nord-Trøndelag patients. Most of the clinical and laboratory
information about all patients were already available and
described elsewhere [8,18,24–28]. Previously available informa-
tion included, in all patients, the iron parameters at diagnosis:
transferrin saturation (TfSat) and serum ferritin (SF); HFE
genotype (all homozygous for the C282Y mutation); and HLA
class I alleles (A and B) as determined by low-resolution DNA-
based techniques (PCR/sequence-specific oligonucleotide probes,
Dynal RELITM SSO, Dynal Biotech Ltd, UK). Values of total
body iron stores (TBIS) estimated by quantitative phlebotomies
were available from 104 patients (34 from Porto, 32 from Alabama
and 38 from Nord-Trøndelag).
Immunophenotyping
Blood counts of T-CD8+ lymphocyte subpopulation were
available for all study participants. T-lymphocyte subpopulations
were determined by FACS analysis using anti-CD3 and anti-CD8
monoclonal antibodies as previously described in detail [24]. We
defined as a ‘‘low CD8 phenotype’’ the finding of CD8+ T
lymphocyte numbers below the 25% percentile in controls. This
value was 3106103/ml in Porto and Alabama patients and
3196103/ml for Nord-Trøndelag patients. Mean values (6
standard deviation) in controls were 433(6168) x103/ml in Porto
and Alabama and 490(6234) x103/ml in Nord-Trøndelag.
Genetic Markers at the MHC Region
In addition to HFE and HLA genotyping, genetic information
on three single nucleotide polymorphisms (SNPs) localized in the
region between HFE and HLA-A was obtained in all patients
included in this study. These SNPs were localized in the genes:
piggyBac transposable element derived 1 (PGBD1, rs1997660), zinc
finger protein 193 (ZNF193, rs7206) and zinc finger protein 165
(ZNF165, rs203878), and defined a SNP microhaplotype of 500
kilobases (kb). These were the SNP microhaplotypes previously
described in Porto patients [18] and were determined ‘‘de novo’’
in patients from Alabama by gene sequencing as described in [18]
and in patients from Nord-Trøndelag by hybridization probe
melting curve analysis on the LightCyclerH, Roche Diagnostics.
Details on primer and probe sequences in addition to PCR
conditions for SNP analysis can be provided by request.
Generation of Phased Chromosomes and Haplotype
Construction
HLA A–B haplotypes, and the SNP microhaplotypes defined by
the genes PGBD1, ZNF193 and ZNF165, were defined in HH
patients by family segregation whenever informative family
members were available. Otherwise they were inferred by the
PHASE program.
Statistical Methods
Associations of HLA alleles and haplotypes in chromosomes
carrying the C282Y mutation in HFE were tested by the Chi-
square test by comparison of their frequencies in HH patients from
the 3 different regions of Porto, Alabama and Nord-Trøndelag
with those of the respective reference normal populations. For the
purpose of statistical analysis, only alleles or haplotypes with
frequencies respectively higher than 10% and 7% in any of the
tested population were considered. Information about HLA allele
and haplotype reference frequencies in the normal populations
from Porto (north Portugal) was obtained at the ‘‘Allele*Frequen-
cies in worldwide populations’’ database [30]. Frequencies for the
Alabama control population were reviewed from the data
previously analyzed by Barton and co-workers [26]. Frequencies
in the non-Sami population from Norway were obtained from the
data described by Harbo et al. 2009 [29], also published at the
‘‘Allele*Frequencies in worldwide populations’’ database [30]. In
order to eliminate the artificially lowered frequencies in HH
chromosomes of other alleles and haplotypes that were due to the
relatively high frequencies of alleles A*03 and B*07 and the
haplotype A*03–B*07, we estimated (in patients and respective
controls) ‘‘corrected’’ allele and haplotype frequencies by sub-
tracting from the denominator respectively the sum of A*03 and
B*07 alleles or the number of A*03–B*07 haplotypes. These
corrected frequencies allowed a more meaningful comparison
between frequencies in HH and control chromosomes, as
originally described by Marcel Simon and co-workers [4]. To
analyze the relative strength of HLA allele or haplotype
associations, the etiological fraction delta (d) was calculated as
described according to the formula d= (FAD-FAP)/(1-FAP) where
FAD is the allele frequency in HH chromosomes and FAP the
allele frequency in control chromosomes [31–33]. In the case of
multiple comparisons we used the Bonferroni correction to test for
the significance of differences.
To investigate the association of CD8+ T lymphocyte numbers
with particular genotypes, we assigned to each chromosome the
value of CD8+ T lymphocytes of the respective carrier. Differences
in mean CD8+ T lymphocyte values among groups were tested by
the Student’s T-test or the One-Way analysis of variance
(ANOVA) as appropriate. In addition, patients with CD8+ T
lymphocyte numbers below the 25% percentile of the respective
controls were selected and their chromosomes assigned as ‘‘low
CD8 phenotype’’ cases. Differences in the relative frequencies of
‘‘low CD8 phenotype’’ cases among groups were tested by the
Chi-square test.
Quantitative measures of iron parameters were also compared
among the 3 populations of HH patients from Porto, Alabama and
Nord-Trøndelag. Because of skewness in the distribution of serum
ferritin and total body iron stores, for statistical purposes the
logarithmic transformation was applied to those values. For
representation in table and figure, however, the non-transformed
values were used. Differences in means among groups were tested
by One-Way analysis of variance (ANOVA) or the Student’s T-test
as appropriate.
Data were analyzed by Statgraphics software (Statgraphics
Graphics System, version 7.0). Values of P,0.05 were defined as
significant.
MHC Haplotypes in Hereditary Hemochromatosis
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Results
1. Clinical Heterogeneity among the HH Populations
from Porto, Alabama and Nord-Trøndelag
A summary of the iron-related parameters of the HH patients
from Porto, Alabama and Nord-Trøndelag is provided in Table 1,
where values are given according to gender. Significant differences
among the 3 populations of patients were observed in males for
TfSat, SF, and TBIS, with P values ,0.00001 in all cases. These
differences were explained by a more severe expression in patients
from Porto and a milder expression in Nord-Trøndelag patients.
In females, SF (P,0.00001) and TBIS (P,0.04) were also
significantly different among the 3 populations, with Porto and
Nord-Trøndelag patients having respectively the highest and
lowest values. The HH cohort from Nord-Trøndelag was the only
one in which patients were identified in screening programs.
Moreover, previous studies in the same population showed that, in
general, Nord-Trøndelag patients have a low prevalence of clinical
symptoms and less severe iron overload [27,28].
2. Analysis of Genetic Markers between HFE and HLA-B in
the HH Populations from Porto, Alabama and Nord-
Trøndelag
From the study of 304 HH patients with C282Y homozygosity
from three geographically distant regions, namely Porto, Portugal
(n = 65), Alabama, USA (n= 57) and Nord-Trøndelag, Norway
(n = 182), we obtained respectively 130, 114 and 364 chromo-
somes carrying HFE C282Y. These were genetically characterized
with 5 different markers including HLA-A alleles, HLA-B alleles,
and SNPs in the genes PGBD1, ZNF193 and ZNF165. HLA A–B
haplotypes and SNP microhaplotypes were assigned by family
segregation, or generated by PHASE in patients without available
informative family members (see Methods).
HLA-A and HLA-B allele frequencies were first analyzed in HH
chromosomes from the three populations. Results are summarized
in Table 2 (uncorrected data are shown in Table S1). As expected
from all previously published studies of HLA associations in HH,
the most common HLA-A and B alleles in chromosomes from all
the three HH populations from Porto, Alabama and Nord-
Trøndelag were A*03 (respectively 0.408, 0.474 and 0.420) and
B*07 (respectively 0.238, 0.307 and 0.288); these frequencies were
significantly different from those of the corresponding controls
(Table 2). The strength of these significant associations was
measured by estimating the etiological fraction delta (see Methods)
being similar in all populations (Table 2). After correcting for the
strong effect of A*03 and B*07 on other allele frequencies (see
Methods), other significantly associated HLA alleles were found in
the populations from Porto (A*01, B*08 and B*40) and Nord-
Trøndelag (A*11, B*14 and B*44). In Alabama patients, the only
additional HLA allele with a statistically significant association was
B*14, suggesting that Alabama patients represent a genetically
more conserved population.
The most prevalent HLA A–B haplotype in the three
populations from Porto, Alabama and Nord-Trøndelag was
A*03–B*07, the proportion of its carriers being 0.169, 0.272 and
0.214, respectively (see also Table 2). Although these haplotype
frequencies do not differ statistically among the different
populations (shown in Supplementary Table 1), the strength of
their associations to HH, as measured by the etiological fraction
delta, is stronger in Alabama (d=0.247) than in Nord-Trøndelag
(d=0.164) or Porto (d=0.158), suggesting a more recent founder
effect in Alabama HH patients. This interpretation is also
consistent with our observation that the prevalence of HLA-A
and -B alleles and haplotypes is less diverse in Alabama patients
than in Porto or Nord-Trøndelag patients. After we corrected for
the predominance of A*03–B*07 haplotypes on other haplotype
frequencies (see Methods), the next most common HLA haplotype
found in patients from all populations was A*01–B*08, although
the respective frequencies of A*01–B*08 did not differ significantly
from those in the respective control populations. The A*03–B*14
haplotype also occurred in hemochromatosis chromosomes from
Alabama and Nord-Trøndelag patients. The significance of this
association could be defined only in the Alabama population due
to lack of sufficient available information about control subjects in
Porto and Nord-Trøndelag. Nevertheless, its significance might be
supported by the very low frequencies found in controls from
Scandinavia [34]. The haplotype A*02–B*44, a very common
haplotype in normal Caucasian populations, was found at similar
frequencies in all non-A*03–B*07-carrying chromosomes from the
three present populations. These respective frequencies did not
differ significantly from those in the respective control subjects.
We next analyzed the SNP microhaplotypes defined by the
SNPs in the genes PGBD1, ZNF193 and ZNF165 in the three
Table 1. Iron parameters (at diagnosis) in HH patients from Porto, Alabama and Nord-Trøndelag.
N TfSat (%) SF (ng/ml) TBIS (g)
HH male patients from:
Porto 43 90614 (63–123) 17506295 (163–7685) 7.9360.78 (2.19–17.40)
Alabama 32 73617 (41–100) 815682 (123–2119) 3.6660.50 (0.40–10.40)
Nord-Trøndelag 103 8169 (58–100) 541663 (27–3511) 3.2360.47 (1.12–15.32)
P value ,0.00001 ,0.00001 ,0.00001
HH female patients from:
Porto 22 81618 (55–111) 5436286 (67–3954) 3.2061.33 (1.10–13.80)
Alabama 25 74620 28–100) 433678 (65–1892) 1.9360.27 (0.40–5.60)
Nord-Trøndelag 79 73612 (51–97) 172627 (16–1151) 1.6560.30 (0.89–4.32)
P value n.s. ,0.00001 0.040
Transferrin saturation (TfSat) is presented as arithmetic mean6 standard deviation; serum ferritin (SF) and total body iron stores (TBIS) are presented as geometric mean
6 standard error. Minimum-maximum values are in parenthesis. TBIS was available in 34 males from Porto, 32 from Alabama and 38 from Nord-Trøndelag and in 13
females from Porto, 23 from Alabama and 12 from Nord-Trøndelag.
Statistically significant differences (P value indicated) were tested among groups using One-way Anova.
doi:10.1371/journal.pone.0079990.t001
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populations (results shown in Table S1). Previous studies in HH
patients had revealed that the most conserved of these SNP
microhaplotypes was the one designated as A-A-T and that this
microhaplotype is also transmitted in association with a more
severe iron phenotype of HH [18]. This microhaplotype was the
most prevalent in all the populations studied here but its relative
frequency differed significantly among them (P=0.0003). Porto
patients had the highest A-A-T frequency (0.908) and Nord-
Trøndelag patients the lowest (0.765). Among the non-A-A-T SNP
microhaplotypes, the most common was G-G-G, the frequency of
which also differed significantly among the three populations
(P=0.003). G-G-G frequency was highest in Nord-Trøndelag
patients (0.160) and lowest in Porto patients (0.062).
In summary, the observation of differences in the relative
frequencies of the described HLA and SNP markers among the
three geographically distant populations of HH patients support
the postulate that evolutionary histories among populations differ
due to differences in genetic drift and recombination of the HH
founder chromosomes in the respective geographic regions.
3. Haplotype Conservation in HH Patients from Porto,
Alabama and Nord-Trøndelag
We analyzed the degree of haplotype conservation as a measure
of their proximity from the ancestral HH founder chromosomes
by selecting the HH chromosomes carrying the most commonly
associated HLA-A alleles (A*01, A*02 and A*03) and calculating
the degree of conservation (%) of the most common SNP
microhaplotype A-A-T in those chromosomes. Results are shown
in Table 3 and Figure 1. In general, a high degree of conservation
was observed in cohorts from Porto, Alabama and Nord-
Trøndelag for chromosomes carrying A*03 (respectively 94%,
98% and 97%), including the A*03–B*07-carrying chromosomes
(respectively 91%, 100% and 99%). In contrast, significant
differences occurred among the three populations regarding the
conservation of chromosomes carrying A*01 or A*02 alleles
(Table 3). These differences are illustrated in Figure 1, particularly
visible for chromosomes carrying HLA-A*01. In the case of Porto
patients, the SNP microhaplotype A-A-T is conserved in all HLA-
A*01 carrying chromosomes (16/16), including all HLA-A*01–
B*08 carrying chromosomes (7/7). This was not observed in either
Alabama or Nord-Trøndelag. In the case of Alabama patients,
53% (9/17) of HLA-A*01-carrying chromosomes (or 56%, 5/9, of
A*01–B*08 carrying chromosomes) do not conserve the A-A-T
microhaplotype. In Nord-Trøndelag patients, 87% (41/47) of
chromosomes carrying HLA-A*01 (or 86%, 25/29, of A*01–B*08
carrying chromosomes) do not conserve the A-A-T microhaplo-
type. In the Nord-Trøndelag population the A-A-T microhaplo-
type was not conserved in 42% (32/76) of A*02 carrying
chromosomes. In contrast, the percentage of conservation was
96% (22/23) and 100% (18/18) in Porto and Alabama cohorts,
respectively. Taken together, the present results further suggest
that the recombination histories or founder effects of the C282Y-
carrying HH chromosomes differ in the three hemochromatosis
populations studied. This may affect other traits encoded in the
same chromosomal region, including determinants of CD8+ T
lymphocyte numbers or other putative modifiers of iron overload.
4. Associations of the CD8+ T Lymphocyte Phenotype
with MHC Markers in HH Patients
We sought to investigate the association of CD8+ T lymphocyte
numbers with particular MHC markers. First, we analyzed the
distribution of CD8+ T lymphocyte numbers in the three
populations of HH patients, each of whom had C282Y
homozygosity. Low CD8+ T lymphocyte numbers were common
in patients from each geographic region (Fig. 2), but the
distribution of T lymphocyte numbers differed. Patients from
Porto and Alabama had a more striking deviation to low numbers
than patients from Nord-Trøndelag (Fig. 2).
We then analyzed the associations of the ‘‘low CD8 phenotype’’
with particular extended haplotype combinations among the three
different populations. A ‘‘low CD8 phenotype’’ was defined as
CD8+ T lymphocyte numbers below the 25% percentile in the
respective controls, i.e., 3106103/ml for Porto and Alabama, and
3196103/ml for Nord-Trøndelag (see Methods). The extended
haplotype combinations were chosen to reflect the degree of
conservation relative to the most common ancestral haplotype, i.e.,
if the A-A-T microhaplotype was conserved or not and, within A-
A-T conserved haplotypes, if HLA-A*03 was conserved or not
(Table 4). We estimated the frequencies of ‘‘low CD8 phenotype’’
cases for each haplotype combination. The results, illustrated in
Table 4, demonstrate that there are differences among the three
populations. The ‘‘low CD8 phenotype’’ was significantly associ-
ated with the most conserved haplotypes carrying A-A-T and the
HLA-A*03 in the populations from Porto (P= 0.045) and Alabama
(P=0.012) but not in the population from Nord-Trøndelag. These
associations were also reflected on the mean CD8+ T lymphocyte
counts. Values in Porto and Alabama patients were significantly
lower than the expected values in controls (P= 0.0017 and
P= 0.021, respectively). Taken together, the different patterns of
association of the ‘‘low CD8 phenotype’’ with particular extended
haplotype combinations in the three populations of patients
suggest a stronger founder effect in the patients from Porto and
Alabama with fewer recombination events between a putative
locus marking the ‘‘low CD8 phenotype.’’ In patients from Nord-
Trøndelag, genotype/phenotype associations were apparently lost.
5. Associations of the Iron Phenotype with MHC Markers
in HH Patients
In order to analyze the effect of associated SNP microhaplo-
types on the clinical expression of iron overload, HH patients were
divided in two groups, according to the presence, in homozygosity,
of the ancestral SNP microhaplotype A-A-T. For statistical
purposes, males and females were analyzed separately. Results
are presented in Table 5 and Figure 3. No significant differences
were found in females and no significant differences were found for
TfSat in both males and females (Fig.3). In general, the average SF
and TBIS values in male patients were significantly higher
(respectively P= 0.027 and P= 0.021) in those homozygous for
the A-A-T microhaplotype than in those carrying one or more
non-A-A-T microhaplotype. Even if the average SF and TBIS
values in male patients appeared higher in those homozygous for
the A-A-T, no significant differences were seen in the 3 separate
populations (Table 5). In conclusion, these results may support a
general prediction of a more severe iron phenotypes in patients’
populations carrying the conserved A-A-T microhaplotype in
homozygosity, but they also show that, for individual purposes, the
microhaplotype A-A-T cannot be used as a universal marker of
iron phenotype in HH.
Discussion
The question of HLA haplotype conservation in HH has been a
focus of scientific interest for a long time, and several interpre-
tations about its role in the recent evolutionary history of
chromosomes carrying the C282Y mutation have been largely
discussed [3–7,14,17,35,36]. Besides the well described A*03–
B*07 ancestral haplotype [3–7], also the A*01–B*08 haplotype is
MHC Haplotypes in Hereditary Hemochromatosis
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very long and resistant against recombination, and appears to be
derived from a single ancestor [14,17]. The present study explored
the implications of haplotype conservation on HH patient’s
phenotypes. While not confirming the value of the A-A-T
microhaplotype as a universal predictive marker of iron overload
in HH, the study revealed important differences in both the
genetic composition and the genotype/phenotype correlations
among the geographically distant populations which may help
explaining differences in phenotype and local penetrance of the
disease. The most relevant questions raised by these results were:
Why do all A*01–B*08 haplotypes from Porto patients carry the
conserved A-A-T microhaplotype, but only 47% in Alabama and
13% in Nord-Trøndelag? Why don’t we see an association of the
A-A-T microhaplotype with low CD8+ T lymphocytes in the
Nord-Trøndelag population, as we observe in Porto and Alabama?
Could the selection of ‘‘non-conserved’’ chromosomes in HFE
C282Y homozygotes may help us in future to identify the
individual loci contributing to the ‘‘low CD8 phenotype’’ and/or
other novel associated modifiers of iron overload? Could the loss of
A-A-T microhaplotype provide the explanation for the mild
phenotype of A*01–B*08 carriers in particular populations, such
Figure 1. Conservation (%) of the SNP microhaplotype A-A-T according to HLA-A alleles in chromosomes from HH patients. A
comparison of the percent haplotype conservation among the three groups of HH patients from Porto, Alabama and Nord-Trøndelag was done using
the Chi-square test and significant results are indicated by a * (P,0.00001).
doi:10.1371/journal.pone.0079990.g001
Table 3. Comparison of the conservation of the SNP microhaplotype A-A-T in chromosomes of HH patients from Porto, Alabama
and Nord-Trøndelag.
Percentage (n) of haplotypes
Associated HLA alleles
Associated SNP
microhaplotype Porto Alabama Nord-Trøndelag P *
A*01
Conserved A-A-T 100% (16) 47% (8) 13% (6) 2.5261029
Non conserved A-A-T 0 53% (9) 87% (41)
A*02
Conserved A-A-T 96% (22) 100% (18) 58% (44) 3.0661025
Non conserved A-A-T 4% (1) 0 42% (32)
A*03
Conserved A-A-T 94% (50) 98% (53) 97% (148) n.s.
Non conserved A-A-T 6% (3) 2% (1) 3% (5)
Non A*01–A*02–A*03
Conserved A-A-T 74% (28) 76% (19) 89% (78) n.s.
Non conserved A-A-T 26% (10) 24% (6) 11% (10)
*Relative frequencies of conserved and non-conserved haplotypes among three populations were compared using the Chi-square test (P values are indicated).
doi:10.1371/journal.pone.0079990.t003
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as the one described in a former Norwegian province in Sweden
[17]?.
In a recent study, Baschal and co-workers analyzed HLA data
and genotypes for thousands of SNPs across the MHC complex in
Figure 2. Distribution of peripheral blood CD8+ T lymphocytes
in HH patients from Porto, Alabama and Nord-Trøndelag. The
dash lines indicate the mean value observed in the respective control
populations.
doi:10.1371/journal.pone.0079990.g002
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a large number of families, demonstrating the occurrence of
multiple common ‘‘completely’’ conserved complex SNP haplo-
types in the MHC region, several of them influencing disease
susceptibility [37]. They suggested that such conservation could
also occur in other genomic areas and proposed that this type of
analysis of conservation versus sub-conservation of extended
haplotypes may be an important tool for further positioning of
disease-associated loci. In the present study, we took advantage of
the known occurrence of highly conserved MHC-linked haplo-
types in patients with HH and its known association with a
phenotype of low CD8+ T lymphocyte numbers to study the
distribution and composition of the HH-associated chromosomes
and explain differences found in genotype/phenotype correlations
among three geographically distant populations. Although high
frequencies of the low CD8+ T lymphocyte phenotype were found
in all HH populations, the pattern of association of this phenotype
with particular haplotypes differed among patients from the three
geographic regions, possibly reflecting diverse haplotype structures
due to different recombination histories or founder effects.
Haplotype Heterogeneity among Populations
The simple analysis of the distribution of HLA associated
haplotypes (Table 2), in addition to the degree of conservation of
the associated A-A-T SNP microhaplotype (Table 3, Fig. 1) in the
three cohorts of patients from Porto, Alabama and Nord-
Trøndelag, shows that the strong association of HH with the
HLA-A*03–B*07 haplotype is the most consistent observation in
all populations studied, confirming the existence of a common
ancestral haplotype subsequently modified by recombination and
geographical scattering due to migrations [4]. The diversity of
associations with other haplotypes reveals differences among
populations which agree with the expected differences in the
history of their HH-carrying chromosomes, taking into consider-
ation particular founder effects or the time for recombination
events. The most stricking differences are observed in chromo-
somes carrying HLA-A*01 (which include the ancestral HLA-
A*01–B*08), in which the SNP microhaplotype A-A-T was
conserved in 100% chromosomes of Porto patients, while it was
less conserved in patients from Alabama (47%) and much less
conserved in or Nord-Trøndelag patients (13%) (see Fig.1),
Figure 3. Effect of the SNP microhaplotypes on the expression of iron overload. Comparisons of the iron parameters: transferrin saturation
(TfSat), serum ferritin (SF) and total body iron stores (TBIS) between groups of HH patients divided according to the associated SNP microhaplotypes
(A-A-T homozygous or non-A-A-T homozygous). Males are represented by solid circles and females represented by open circles. Significant
differences in the mean values (by the Students T test) are indicated by an *(P =,0.027).
doi:10.1371/journal.pone.0079990.g003
Table 5. Average values of total body iron stores (TBIS) and serum ferritin (SF) of HH male patients according to the associated
SNP microhaplotypes (A-A-T homozygous or non- A-A-T homozygous).
All HH patients HH patients from
Porto Alabama Nord-Trøndelag
Average of TBIS (g) in:
A-A-T homozygous male patients 4.98 [4.24–5.85] (n=77) 8.08 [6.42–10.11] (n = 29) 3.83 [3.01–4.88] (n = 24) 3.62 [2.75–4.76] (n = 24)
Non-A-A-T homozygous male patients 3.37 [2.43–4.69] (n=27) 7.11 [3.07–16.48] (n = 5) 3.23 [1.34–7.75] (n = 8) 2.65[1.87–3.77] (n = 14)
P* 0.021 n.s. n.s. n.s.
Average of SF (ng/ml) in:
A-A-T homozygous male patients 849 [718–1004] (n=124) 1764 [1296–2400] (n = 36) 818 [670–999] (n = 24) 571 [461–707] (n = 64)
Non-A-A-T homozygous male patients 602 [470–771] (n=51) 1652 [576–4737] (n = 5) 806 [402–1616] (n = 8) 496 [381–646] (38)
P* 0.027 n.s. n.s. n.s.
TBIS and SF are presented as geometric mean and 95% Confidence Interval for Mean [Lower Bound - Upper Bound]; the numbers of patients in each group (n) are
indicated in each case.
*(P) Statistical significant differences using the Students T- test (with log transformed values, see methods).
doi:10.1371/journal.pone.0079990.t005
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supporting the different founder effects or distinct recombination
histories in the respective populations. The highest haplotype
diversity observed in the Nord-Trøndelag population is also
consistent with the high frequency of HFE C282Y in Norwegians
[27,28,38], possibly related with characteristics of rapid population
growth that has occurred in northwestern Europe since the Celtic
period [14]. On the contrary, patients from Alabama showed the
lowest haplotype diversity, reflecting a more recent founder effect.
A previous study showed that aggregate ‘‘British Isles’’ or Scotland
indices of ancestry were significantly greater and the proportion of
non-British Isles, non-Native American ancestry was significantly
lower in Alabama hemochromatosis probands with HFE C282Y
homozygosity than in population control subjects [39,40]. These
observations suggest that British Isles ancestry likely accounts for
the relatively high C282Y allele frequency and association of
HLA-A*03–B*07 and HFE C282Y in central Alabama whites.
Therefore, the evidence of a recent founder effect in Alabama HH
patients suggested by the present results agrees with the previous
ancestry studies and with the predominance of English people
among whites who migrated to and settled the geographic area of
the present State of Alabama in the late 18th and early 19th
centuries [41,42]. HLA-A*03–B*14 also occurred in hemochro-
matosis chromosomes from Alabama and Nord-Trøndelag
patients. Although this haplotype is also described as a common
HH ancestral haplotype in hemochromatosis populations in many
northwestern European countries, particularly in Scandinavia
[36], its appearance in Alabama HH patients is unlikely to be
attributed predominantly to Norwegian or other Scandinavian
founders because ancestry reports from these geographic areas of
Europe are rare in Alabama hemochromatosis probands and
population control subjects [39]. Nevertheless this haplotype could
have a common ancestral Irish origin and be spread in Norway by
the close contacts between Ireland and Scandinavia through the
Vickings’ movements [35,36]. In the case of Porto patients, the
relative low diversity of HH haplotypes could be attributed to the
particular demographic characteristics of the Portuguese popula-
tion in the north region namely the unipolar mode of migration
and the low rate of mobility from other regions [43]. Significant
regional differences were previously found in the distribution of
the C282Y mutation in Portugal with the highest frequencies
found in the north of the country [44]. In terms of historical
population settlements, it is well recognized that there is a
geographical and cultural boundary between the north and the
south of Portugal documented by archeological, ethnographic and
linguistic records [43], all favoring the notion that a stronger Celtic
influence in the north could map the founder HH chromosomes in
this region by the 6th century BC. The hypothesis that the later
Nordic/Suevian occupation and settlement, which also occurred
only in the north of the present country, could also contribute to
the increased frequency of the mutation cannot be excluded. The
present results of divergent patterns of haplotype conservation and
genotype/phenotype associations in patients from Porto and
Nord-Trøndelag do not favor a strong Scandinavian HH founder
effect in north Portugal.
Effect of Haplotype Conservation on the CD8+ T
Lymphocyte Phenotype
It is well known that the existence of different founder effects
and different recombination histories at the MHC region affect the
transmission of other genetic traits encoded in the same
chromosomal region [1]. The previously demonstration that
CD8+ T lymphocyte numbers are transmitted in association with
particular HLA haplotypes in Portuguese HH patients [24,25]
prompt us to analyze if the same association was also observed in
the other HH populations, We confirmed that the phenotype of
low CD8+ T lymphocytes was commonly observed in each of the
three populations, but their respective distributions (Fig. 2) and
their genotype/phenotype correlations (Table 4) varied. The ‘‘low
CD8 phenotype’’ was significantly associated with the most
conserved ancestral haplotype carrying A*03-A-A-T in the cohorts
from Porto (n = 50) and Alabama (n= 51) but it was not associated
in a much greater series from Nord-Trøndelag (n = 148). This lack
of association of the common ancestral haplotype with the ‘‘low
CD8 phenotype’’ in Nord-Trøndelag patients is intriguing. One
should stress however, that discrepancies in expected genotype/
phenotype correlations can also be highly informative regarding
the localization of genetic traits. That individual chromosomes
with the same alleles (A*03, A-A-T) may or may not be associated
with the ‘‘low CD8 phenotype’’ indicates that these alleles are not,
by themselves, determinants of the trait, further supporting the
hypothesis of another independent, still unidentified, genetic
marker in the region. The time and place, during the evolutionary
history of the HH chromosomes, when the association occurred
remains unknown. Further studies of genotype/phenotype corre-
lations in other populations with different founder effects could
clarify this question. As suggested by Olsson and co-workers [35],
it would be of great interest to explore further the HLA haplotype/
phenotype correlations in an extended population of patients from
the Trøndelag region, because of its long historic close contacts
with the British islands, the supposed origin of founders of the
‘‘Celtic’’ haplotypes in Scandinavia [35]. On the other hand,
results from Porto and Alabama support the postulate that a major
genetic determinant of CD8+ T lymphocyte numbers is transmit-
ted in linkage disequilibrium with HFE in this ancestral haplotype
and suggest these populations as good targets to further position a
candidate locus associated with the transmission of low CD8+ T
lymphocyte phenotypes. The evidence that the association is lost
not only in chromosomes without the A-A-T SNP microhaplotype
but also, within the A-A-T conserved haplotypes, in chromosomes
without the ancestral A*03 allele (Table 4), favors the localization
of such a putative trait between HLA-A and PGBD1. Future studies
in these populations should consider selecting ‘‘non-conserved’’
chromosomes, i.e., those with discontinuous regions of conserva-
tion to the consensus haplotypes, to facilitate the search for
individual loci contributing to the trait.
Effect of the SNP Microhaplotypes on the Iron Overload
Phenotype
In addition to its association with a ‘‘low CD8 phenotype’’, the
conservation of the ancestral A-A-T microhaplotype had been
previously shown to be associated with a more severe iron
overload phenotype [18]. In the present study we showed that,
although in general, the presence in homozygosity of the A-A-T
microhaplotype was associated to higher values of serum ferritin
and total body iron stores in male patients, this association was not
significantly sustained at the individual populations’ level and
therefore cannot be used as a reliable universal marker of the
phenotypic expression in HH (Table 5). The lack of statistical
power in individual populations could be explained by the low
numbers of non-A-A-T homozygous patients found in each region
together with a high phenotypic diversity in these patients
(reflected in the high range of values shown in Table 5), but it
could also be influenced by genetic differences among populations,
namely the loss of association of the A-A-T microhaplotype with
the putative ‘‘low CD8 phenotype’’ marker in the Nord-Trøndelag
patients. One should also note that these patients were mainly
identified by screening of asymptomatic subjects, therefore
unselected for clinical severity. On the contrary, Porto and
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Alabama, patients were mainly diagnosed on a clinical setting.
Nevertheless, even using the same selection criteria, there are also
great differences in iron loading between Porto and Alabama
patients that could be related with different environmental factors
or local life-style habits, including regular alcohol consumption.
Therefore, further studies are still needed in larger populations
and with a higher density mapping of the region, in order to find a
more specific and universal surrogate marker of iron overload
severity in HH.
Concluding Remarks
We conclude that the evolutionary history of long extended
haplotypes on chromosome 6p21.3 could account for heteroge-
neity within the haplotypes and consequent differences in the
phenotypic expression of persons with HFE C282Y related HH.
These observations have important implications for the interpre-
tation of genotype/phenotype association studies in HH such as in
the case of MHC loci associated with the transmission of the
phenotype of low CD8+ T lymphocyte numbers where differences
occur among HH populations from geographically distant regions
(namely in north Portugal, Norway and Alabama, USA) or the
association of MHC markers with iron overload. The effect of
haplotype conservation may also have implications for under-
standing differences in disease penetrance or the consequences of
patients’ sampling according to different detection methods.
Although no consistent evidence is given about the predictive
value of the A-A-T microhaplotype for individual purposes, one
may predict that, in general, any cohort of severe or symptomatic
HH patients may contain a high frequency of this conserved
ancestral haplotype associated with a ‘‘low CD8 phenotype’’, such
as we have consistently found in Portuguese patients. On the
contrary, in populations where programs for screening of
asymptomatic cases are implemented, such as in Norway, it will
be more probable to find HH patients with non-conserved
haplotypes that are not associated with low CD8+ T lymphocytes.
It remains unknown whether the severity of iron overload depends
directly on the ‘‘low CD8 phenotype’’ or whether another
independent modifier of the iron phenotype is inherited in linkage
disequilibrium. Naturally, future positional cloning of a long-
sought major genetic trait in MHC associated with the transmis-
sion of CD8+ T lymphocyte numbers [45] should provide answers
to this question.
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